Industry News

Biogen, AbbVie Report Positive Top-Line Results from Phase 3 Trial of Daclizumaba for MS
Regulus Appoints Paul C. Grint, M.D. as Chief Medical Officer - Recognized Industry Leader Brings Extensive Clinical and Product Development Expertise -
Sequenom Laboratories and Quest Diagnostics Collaborate to Expand Patient Access to the MaterniT21� PLUS Noninvasive Prenatal Test
Agios Pharmaceuticals Announces Orphan Drug Designation of AG-221 for Treatment of Acute Myelogenous Leukemia
Largest-Ever TMF Survey Reveals Lagging Technology Adoption and Manual Processes Significantly Impacting Clinical Trial Operations
DARA BioSciences' KRN5500 Granted Orphan Drug Designation by FDA for Treatment of Multiple Myeloma Second Orphan Drug Designation Received in 2014 for Key Development Asset
Tennessee health officials strengthen stance on e-cigarettes
Medtronic to acquire Covidien in $42.9 billion deal
Fortune Oil & Gas Updates on Business Direction with the Acquisition of Manzo Pharmaceuticals
FDA Classifies Nonabsorbable Expandable Hemostatic Sponge for Temporary Internal Use as Class II
FDA approves Lymphoseek to help determine the extent of head and neck cancer in the body
Sanofi and Medtronic to Form Strategic Alliance in Diabetes to Improve Patient Experience and Outcomes Initial focus on insulin-device combinations and care management services
Astrazeneca buys licence for new anti-asthma treatment
Merck Launches Global Patient Registry Supporting Expanded Commitment to Real-World Outcomes Research in Type 2 Diabetes
Hospira Shares Results From Randomised Trials Showing Biosimilar Monoclonal Antibody, Inflectra(TM), Demonstrates Comparable Reductions in Disease Activity to Remicade� Over One Year
Covidien moving 100 jobs from Boulder to Indiana
Ocugen Receives Orphan Designation for OCU100 to Treat Retinitis Pigmentosa Ocugen, Inc.
Shire To Conduct Studies Of Vyvanse For ADHD In Children Aged 4 And 5
Shire To Conduct Studies Of Vyvanse For ADHD In Children Aged 4 And 5
FDA approves Bayer's Gadavist Injection as the first magnetic resonance contrast agent for evaluation of breast cancer in the United States
FDA approves Bayer's Gadavist (gadobutrol) Injection as the first magnetic resonance contrast agent for evaluation of breast cancer in the United States - Gadavist-enhanced breast MRI demonstrated superior sensitivity (range: 80-89%) for the
FDA Approves ALOX to Prevent Nausea and Vomiting due to Chemotherapy in Children
Teva Received FDA Approval for QVAR with Dose Counter Asthma
Covidien Neurovascular Micro Catheter Receives FDA Approval
Merck Serono Announces FDA Clearance for Auxogyn's Early Embryo Viability Assessment System